RESEARCH

Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors

Emiliano Calvo1 · Cristiana Sessa2 · Guilherme Harada3 · Maria de Miguel1 · Carmen Kahatt4 · Xarles Erik Luepke-Estefan4 · Mariano Siguero4 · Carlos Fernandez-Teruel4 · Martin Cullell-Young4 · Anastasios Stathis2 · Alexander Drilon3

Received: 13 June 2022 / Accepted: 3 July 2022 / Published online: 10 August 2022 © The Author(s) 2022

Summary
Lurbinectedin and paclitaxel showed synergism in preclinical studies and have non-completely overlapping toxicity profiles. This phase I trial evaluated a combination of paclitaxel and lurbinectedin with/without bevacizumab in advanced tumors. This trial was divided into Group A, which evaluated weekly paclitaxel (60 or 80 mg) plus lurbinectedin (3.0–5.0 mg flat dose [FD] or 2.2 mg/m²) every 3 weeks in advanced solid tumors; and Group B, which evaluated bevacizumab (BEV, 15 mg/kg) added to the recommended dose (RD) defined in Group A in advanced epithelial ovarian or non-small cell lung cancer (NSCLC). 67 patients (A, n = 55; B, n = 12) were treated. The RD was paclitaxel 80 mg/m² on Day (D)1,D8 plus lurbinectedin 2.2 mg/m² on D1. At this RD, myelotoxicity was reversible and manageable, and most non-hematological toxicities were mild/moderate. Adding BEV did not notably change tolerability. Twenty-five confirmed responses were observed: 20/51 evaluable patients in Group A (overall response rate [ORR] = 39% at all dose levels and at the RD), and 5/10 evaluable patients in Group B (ORR = 50%). Most responders had breast (n = 7/12 patients), small cell lung (SCLC) (n = 5/7), epithelial ovarian (n = 3/9) and endometrial cancer (n = 3/11) in Group A, and epithelial ovarian (n = 3/4) and NSCLC (n = 2/6) in Group B. Clinical benefit rate was 61% in Group A (58% at the RD), and 90% in Group B. No major pharmacokinetic drug-drug interactions were observed. Paclitaxel/lurbinectedin and paclitaxel/lurbinectedin/BEV are feasible combinations. Further development is warranted of paclitaxel/lurbinectedin in SCLC, breast, and endometrial cancer, and of paclitaxel/lurbinectedin/BEV in epithelial ovarian cancer.

Keywords Lurbinectedin · Paclitaxel · Bevacizumab · Phase I study

Introduction
Lurbinectedin (Zepzelca®) is a synthetic tetrahydroisoquinoline alkaloid structurally related to trabectedin. It inhibits oncogenic transcription primarily through binding to the exocyclic amino group of guanine-rich DNA sequences around promoters of protein-coding genes, thereby altering the 3D DNA structure and evicting oncogenic transcription factors from their binding sites, thus halting their aberrant transcription programs [1–3]. Lurbinectedin adducts can stop transcribing (phosphorylated) RNA polymerase II, decreasing mRNA synthesis and inducing the ubiquitination and degradation of RNA polymerase II inhibition [4]. Lurbinectedin adducts may also trick the nucleotide excision repair system, favoring the production of DNA double-strand breaks and triggering apoptotic cell death [5]. Lurbinectedin monotherapy has been approved in the U.S. and other countries for the treatment of adult patients with metastatic small cell lung cancer (SCLC) and disease progression on or after platinum-based chemotherapy.

The first-in-human phase I study defined a recommended dose (RD) of 7 mg flat dose (FD) for single-agent lurbinectedin as a 1-h intravenous (i.v.) every 3 weeks (q3wk) [6]. Severe but transient neutropenia, and mild fatigue, nausea and vomiting, were common at this RD. The pharmacokinetic (PK) profile of lurbinectedin showed dose linearity, high interpatient variability, and a long median half-life (70.6 h at the RD).
Preclinical studies showed improved antitumor activity for lurbinectedin with taxanes. In vivo, synergism was observed with lurbinectedin and paclitaxel in mice bearing gastric, ovarian, non-small cell lung cancer (NSCLC), breast or prostate xenografted tumors [7]. Lurbinectedin and paclitaxel have toxicity profiles that are not completely overlapping. Both are cytochrome CYP3A4 substrates; hence, PK interactions by competitive inhibition of this enzyme system cannot be discarded.

Bevacizumab (BEV) is a humanized monoclonal antibody against the circulating vascular endothelial growth factor that inhibits tumor angiogenesis. BEV primarily acts in the tumor microenvironment, with very little hematological toxicity. The combination of chemotherapy with BEV has been associated with improved clinical activity compared with chemotherapy alone [8–13].

The aim of this phase I study was to determine the maximum tolerated dose (MTD) and the RD, safety profile, activity and PK of lurbinectedin combined with weekly paclitaxel, with or without BEV, in advanced solid tumor patients.

**Patients and methods**

Supplementary Information includes details regarding study design and eligibility criteria. In brief, patient accrual began in Group A (paclitaxel and lurbinectedin) at a starting dose of paclitaxel 60 mg/m² plus lurbinectedin 3.0 mg flat dose (FD). Treatment initially consisted of escalating doses of paclitaxel as 1-h i.v. infusions on Day (D) 1, D8 and D15, followed by lurbinectedin as a 1-h i.v. infusion on D1, both every three weeks (q3wk). After DL3, the paclitaxel schedule was changed to 1-h i.v. infusions on D1 and D8 q3wk owing to a high incidence of D15 dose omissions in DL3. Furthermore, during dose escalation lurbinectedin was converted to a body surface area (BSA)-based dose. Once the RD for paclitaxel and lurbinectedin had been determined in Group A, patients were enrolled in Group B and received this RD supplemented with BEV 15 mg/kg as a 30–90 min i.v. infusion on D1 q3wk.

In both groups, paclitaxel was discontinued after Cycle 6; patients still on treatment continued receiving lurbinectedin alone (Group A) or lurbinectedin plus BEV (Group B) at the same dose. Treatment was administered until disease progression, unacceptable toxicity, intercurrent illness precluding study continuation, patient refusal and/or non-compliance with study requirements, treatment delay > 15 days (except if with clear clinical benefit), and > 2 dose reductions.

**Study assessments**

Supplementary Information includes definitions for dose-limiting toxicities (DLTs) and details regarding safety, efficacy and PK assessments.

Adverse events (AEs) and laboratory abnormalities were graded with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.4 [14], and coded using the Medical Dictionary for Regulatory Activities (MedDRA) v.16.0. Antitumor activity was evaluated every three cycles according to the RECIST v.1.1 [15]. The PK analysis was conducted on 12 blood samples collected from each patient during Cycle 1 to quantify lurbinectedin and paclitaxel plasma concentrations.

**Statistical analysis**

Continuous variables were presented with summary statistics and categorical variables in frequency tables. Time-to-event variables were calculated using Kaplan–Meier approach. Binomial exact distribution was used to calculate 95% confidence intervals (95%CIs) for categorical variables. Blood and plasma concentration–time profiles were analyzed by standard non-compartmental methods. Individual PK parameters were tabulated and summarized.

**Results**

**Patient characteristics**

Sixty-nine patients were enrolled in this study: 55 in Group A (paclitaxel/lurbinectedin) and 14 in Group B (paclitaxel/lurbinectedin/BEV). Patient characteristics at baseline are summarized in Table 1.

Most of the 55 patients (73%) enrolled at all dose levels in Group A were female, with median age 57 years (range, 31–74 years). The most common primary tumors comprised endometrial (n = 13 patients, 24%), breast (n = 12, 22%), epithelial ovarian, NSCLC (n = 9, 16% each) and SCLC (n = 7, 13%). The median number of metastatic sites was 2 (range, 1–6 sites). The median number of lines of all prior therapies for advanced disease was 2 (range, 0–7 lines), and the most common prior therapies were platinum compounds (82%) and taxanes (60%). Thirty-seven patients in Group A were enrolled at the RD. Twenty-six of these patients (70%) were female, with a median age of 61 years (range, 38–74 years). Their most common primary tumors were endometrial (35% of patients), breast (22%), NSCLC (16%), SCLC (14%) and epithelial ovarian (8%). The median number of metastatic
### Table 1  Baseline characteristics of patients

|                     | Group A (Paclitaxel / lurbinectedin) | Group B (Paclitaxel / lurbinectedin / BEV) |
|---------------------|--------------------------------------|-------------------------------------------|
|                     | RD (n=37)                            | All dose levels (n=55)                     | RD + BEV (n=14) |
| **Gender**          |                                      |                                            |                 |
| Female              | 26 (70%)                             | 40 (73%)                                  | 8 (57%)         |
| Male                | 11 (30%)                             | 15 (27%)                                  | 6 (43%)         |
| **Median age, years (range)** | 61 (38–74)                           | 57 (31–74)                                | 57 (47–72)      |
| **ECOG performance status** |                                   |                                            |                 |
| 0                   | 22 (59%)                             | 33 (60%)                                  | 11 (79%)        |
| 1                   | 15 (41%)                             | 22 (40%)                                  | 3 (21%)         |
| **Median BSA, m² (range)** | 1.8 (1.4–2.2)                   | 1.8 (1.4–2.4)                             | 1.8 (1.4–2.2)   |
| **Primary tumors**  |                                      |                                            |                 |
| Breast              | 8 (22%)                              | 12 (22%)                                  |                 |
| Endometrial         | 13 (35%)                             | 13 (24%)                                  |                 |
| Epithelial ovarian  | 3 (8%)                               | 9 (16%)                                   | 7 (50%)         |
| NSCLC               | 6 (16%)                              | 9 (16%)                                   | 7 (50%)         |
| SCLC                | 5 (14%)                              | 7 (13%)                                   |                 |
| Other a             | 2 (5%)                               | 5 (9%)                                    |                 |
| **Bulky disease (any target lesion ≥ 50 mm)** | 5 (14%)                           | 8 (15%)                                   | 1 (7%)          |
| **Median number of metastatic sites (range)** | 2 (1–6)                             | 2 (1–6)                                   | 3 (1–6)         |
| **Most common sites of disease** |                                      |                                            |                 |
| Liver               | 15 (41%)                             | 24 (44%)                                  | 4 (29%)         |
| Lung                | 15 (41%)                             | 24 (44%)                                  | 8 (57%)         |
| Lymph nodes         | 23 (62%)                             | 33 (60%)                                  | 7 (50%)         |
| Peritoneum          | 12 (32%)                             | 19 (35%)                                  | 6 (43%)         |
| **Prior treatment for advanced disease** |                                      |                                            |                 |
| Median (range)      | 1 (0–4)                              | 2 (0–7)                                   | 2 (0–4)         |
| 0 b                 | 1 (3%)                               | 1 (2%)                                    | 1 (7%)          |
| 1                   | 20 (54%)                             | 25 (45%)                                  | 5 (36%)         |
| 2                   | 8 (22%)                              | 14 (25%)                                  | 3 (21%)         |
| 3 or more           | 8 (22%)                              | 15 (27%)                                  | 5 (36%)         |
| **Prior anticancer agents** |                                      |                                            |                 |
| Anthracyclines and related substances | 16 (43%)                       | 24 (44%)                                  | 4 (33%)         |
| Aromatase inhibitors | 3 (8%)                             | 8 (15%)                                   |                 |
| Folic acid analogues | 4 (11%)                           | 7 (13%)                                   | 7 (58%)         |
| Monoclonal antibodies | 5 (14%)                         | 11 (20%)                                  | 4 (33%)         |
| Nitrogen mustard analogues | 12 (32%)                     | 15 (27%)                                  |                 |
| Platinum compounds  | 32 (87%)                             | 45 (82%)                                  | 12 (100%)       |
| Podophyllotoxin derivatives | 6 (16%)                         | 8 (15%)                                   | 1 (8%)          |
| Pyrimidine analogues | 13 (35%)                           | 20 (36%)                                  | 5 (42%)         |
| Taxanes             | 24 (65%)                             | 33 (60%)                                  | 8 (67%)         |

Data shown are number of patients (percentage), except for median (range)

a Includes adenocarcinoma or carcinoma of unknown primary site (n=2), cervical cancer (n=1), platinum-refractory GCTs (n=1), and HNSCC (n=1)
b These patients received prior therapy in the adjuvant setting

c Calculated on the number of patients treated (n=55 at all dose levels in Group A, n=37 at the RD in Group A, and n=12 in Group B)

BEV bevacizumab, BSA body surface area, CNS central nervous system, ECOG Eastern Cooperative Oncology Group, GCT germ cell tumor, HNSCC head and neck squamous cell carcinoma, NSCLC non-small cell lung cancer, RD recommended dose, SCLC small cell lung cancer
sites was 2 (range, 1–6 sites) and the median number of lines of prior therapy for advanced disease was 1 (range, 0–5 lines), with the most common prior therapies being platinum compounds (87%) and taxanes (65%).

Most of the 14 patients (57%) enrolled in Group B were also female. The median age was 57 years (range, 47–72 years). All patients had epithelial ovarian cancer or NSCLC (n = 7 patients each). The median number of metastatic sites was 3 (range, 1–6 sites), and the median number of lines of prior therapy for advanced disease was 2 (range, 0–4 lines). All 14 patients had been pre-treated with platinum compounds; other prior therapies were taxanes (67%) and folic acid analogues (58%).

### Treatment administration

In Group A, 55 enrolled patients were treated at five dose levels: DL1 (n = 3 patients), DL2 (n = 3) and DL3 (n = 6) with paclitaxel on D1, D8 and D15 q3wk, and DL4 (n = 6) and DL5 (n = 37) with paclitaxel on D1 and D8 q3wk (see Supplementary Information). A total of 392 treatment cycles were administered at all dose levels (median: 5.0 cycles per patient); 20 patients (36%) were still on treatment after Cycle 6 and switched to single-agent lurbinectedin. At DL5 (the RD), 256 treatment cycles were given (median: 5.0 cycles per patient); 25 patients (41%) switched to single-agent lurbinectedin after Cycle 6. Most treatment discontinuations (44 of 55 patients [80%] at all dose levels; 30 of 37 patients [81%] at DL5 [the RD]) were due to disease progression. No treatment-related discontinuations occurred at the RD. The median time on treatment was 4.8 months, both at all dose levels and at the RD. The median dose intensities (DIs) at the RD were 49.1 mg/m²/week for paclitaxel and 0.7 mg/m²/week for lurbinectedin, and the median relative DIs compared to the initially planned dose were 92% and 98%, respectively. At the RD, 6 patients (16%) had cycle delays and 7 patients (19%) had study drug dose reductions due to treatment-related reasons (mostly hematological toxicity).

In Group B, 12 of the 14 enrolled patients received a total of 111 treatment cycles at a dose of paclitaxel 80 mg/m² on D1 and D8 and lurbinectedin 2.2 mg/m² on D1 q3wk supplemented with BEV 15 mg/kg on D1 q3wk (median: 9.5 cycles per patient). Two patients were withdrawn from the study before receiving the first dose due to disease-related bowel obstruction (n = 1), and patient refusal (n = 1). Eight patients (67%) were still on treatment after Cycle 6 and switched to lurbinectedin and BEV. Most treatment discontinuations (8 of 12 patients [67%]) were due to disease progression. One discontinuation was due to treatment-related thrombocytopenia. The median time on treatment was 7.9 months. The median DIs were 50.3 mg/m²/week for paclitaxel, 0.7 mg/m²/week for lurbinectedin and 5.0 mg/m²/week for BEV; the median relative DIs were 94%, 100% and 99%, respectively. Three patients (25%) had cycle delays and 2 patients (17%) had study drug dose reductions owing to treatment-related reasons (mostly hematological toxicity).

### Dose escalation and recommended dose

Fifty-two treated patients in Group A were evaluable for DLTs (see Supplemental information). Three patients were non-evaluable because they did not receive a complete Cycle 1 due to disease-related events (n = 2), or because of lack of laboratory assessment for DLT evaluation during Cycle 1 (n = 1). Paclitaxel was initially administered at a schedule of D1, D8 and D15 q3wk. No DLTs occurred at the first two dose levels. Two of 6 patients at DL3 (paclitaxel 60 mg/m², lurbinectedin 5.0 mg FD) had delayed DLTs (grade 3 or 4 neutropenia after Cycle 1). After DL3, the paclitaxel schedule was changed to D1 and D8 q3wk owing to the finding of a high incidence (4 of 6 patients) of paclitaxel dose omissions due to treatment-related neutropenia during Cycle 1 at DL3. At DL4 (paclitaxel 80 mg/m², lurbinectedin 5.0 mg FD), 3 of 6 patients had DLTs (grade 3/4 neutropenia > 7 days [n = 2]; or lack of compliance due to neutropenia [n = 1]); as a result, this dose was defined as the MTD. None of the first 6 patients at DL5 (paclitaxel 80 mg/m², lurbinectedin 4.0 mg FD) had DLTs. The DL5 cohort was then expanded, converting lurbinectedin to a BSA-based dose of 2.2 mg/m² (calculated by dividing 4.0 mg FD by a BSA of 1.8 m²). Six of 28 patients in the expanded DL5 cohort (paclitaxel 80 mg/m², lurbinectedin 2.2 mg/m²) had DLTs (grade 3 neutropenia > 7 days alone [n = 2] or with grade 3 anemia [n = 1], grade 4 neutropenia > 3 days [n = 1], grade 2 anemia and grade 2 tooth infection (with concomitant neutropenia) [n = 1], and grade 3 vomiting [n = 1]), thereby confirming paclitaxel 80 mg/m² on D1 and D8 plus lurbinectedin 2.2 mg/m² on D1 as the RD in Group A, with prolonged severe neutropenia as the most common DLT. No episodes of febrile neutropenia occurred as DLTs in Group A.

All 12 patients treated with paclitaxel 80 mg/m² on D1 and D8 plus lurbinectedin 2.2 mg/m² on D1 and BEV 15 mg/kg on D1 in Group B were DLT evaluable (see Supplemental information). Three patients had DLTs: grade 3 febrile neutropenia (n = 1), grade 4 neutropenia > 3 days (n = 1), and grade 4 large intestine perforation (n = 1, a patient with ovarian cancer). No treatment-related deaths occurred in Group B. The percentage of patients with DLTs in Group B (3/12 patients; 25%) in the absence of treatment-related mortality was below the threshold of one third of patients defined in the study protocol, thereby confirming the feasibility of adding BEV to the RD defined in Group A.
Safety

All treated patients were evaluable for safety. Treatment-related AEs and laboratory abnormalities at the RD in Group A and in Group B are shown in Table 2.

Thirty-four of 37 patients (92%) treated at the RD in Group A had at least one treatment-related AE. Most of these AEs were grade 1/2, with the most common being fatigue (59% of patients), nausea (54%), vomiting (46%), peripheral sensory neuropathy (27%), diarrhea and alopecia (24% each). Grade ≥ 3 treatment-related AEs comprised catheter site cellulitis, diarrhea, fatigue, maculopapular rash, nausea, sepsis, and vomiting in one patient each (3%). Of these, only sepsis reached grade 4. Hematological abnormalities consisted of anemia (94%; grade 3 in 22%), neutropenia (72%; grade 3/4 in 58%) and thrombocytopenia (47%; grade 3 in 17%); one patient (3%) had treatment-related grade 3 febrile neutropenia. The most frequent biochemical abnormalities were increases in creatinine (81%), alanine aminotransferase (ALT) (61%; grade 3/4 in 14%), aspartate aminotransferase (AST) (53%; grade 3/4 in 8%) and AP (42%, grade 3 in

Table 2 Treatment-related adverse events (> 10% of patients) and laboratory abnormalities (hematological and biochemical) at the recommended dose for phase II studies, with or without BEV

| NCI-CTCAE grade | Group A (Paclitaxel 80 mg/m² / lurbinectedin 4.0 mg FD or 2.2 mg/m²) (n = 37) | Group B (Paclitaxel 80 mg/m² / lurbinectedin 2.2 mg/m² / BEV 15 mg/kg) (n = 12) |
|-----------------|---------------------------------------------|---------------------------------------------|
| Hematological laboratory abnormalities | | |
| Anemia * | 72 22 94 | 83 17 100 |
| Neutropenia * | 14 31 28 72 | 42 25 67 |
| Thrombocytopenia * | 31 17 47 | 25 17 42 |
| Biochemical laboratory abnormalities | | |
| ALT increased * | 47 11 3 61 | 75 75 |
| AP increased * | 36 6 42 | 42 42 |
| AST increased * | 44 6 3 53 | 42 42 |
| Bilirubin increased * | 11 3 14 | | |
| CPK increased * | 11 11 | 17 17 |
| Creatinine increased * | 81 81 | 75 75 |
| Adverse events | | |
| Abdominal abscess | | 17 17 |
| Alopecia | 24 24 | 42 42 |
| Constipation | 8 8 | 25 25 |
| Decreased appetite | 16 16 | 25 25 |
| Diarrhea | 22 3 24 | 33 33 |
| Dysgeusia | 11 11 | | |
| Dyspepsia | 11 11 | 17 17 |
| Epistaxis | | 17 17 |
| Fatigue | 57 3 59 | 50 8 58 |
| Febrile neutropenia | 3 3 | 17 17 |
| Hypertension | | 25 25 |
| Nausea | 51 3 54 | 50 50 |
| Peripheral sensory neuropathy | 27 27 | 17 17 |
| Pulmonary embolism | | 17 17 |
| Rash maculo-papular | 3 3 5 | 17 17 |
| Vomiting | 43 3 46 | 8 8 |

The percentage of patients with each adverse event is specified

Hematological and biochemical abnormalities are shown regardless of relationship to treatment

* Missing data for one patient in Group A

ALT alanine aminotransferase, AP alkaline phosphatase, AST aspartate aminotransferase, BEV bevacizumab. CPK creatine phosphokinase, FD flat dose, NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
Six patients (18.9%) required red blood cell (RBC) transfusions and four patients (10.8%) required secondary granulocyte colony-stimulating factor (G-CSF) support. No treatment discontinuations or deaths occurred due to toxicity.

All 12 treated patients in Group B had at least one treatment-related AE. Most of these AEs were also grade 1/2, with the most frequent being fatigue (58%), nausea (50%), alopecia (42%) and diarrhea (33%). Grade ≥3 treatment-related AEs comprised abdominal abscess and pulmonary embolism in two patients each (17%), and colonic fistula, fatigue, gastrointestinal fistula, large intestine perforation, and septic shock in one patient each (8%); of these, only the intestinal perforation was grade 4. Hematological abnormalities consisted of anemia (all patients; grade 3 in 17%), neutropenia (67%; all grade 3/4) and thrombocytopenia (42%; grade 3 in 17%). Two patients (17%) had grade 3 febrile neutropenia. All biochemical abnormalities were grade 1/2, with the most common being increases in creatinine and ALT (75% each), AST and AP (42% each). Three patients (25.0%) required RBC transfusions and three (25.0%) were given G-CSF support. One patient discontinued treatment due to toxicity (grade 4 large intestine perforation). No deaths occurred due to toxicity.

Fig. 1 Maximum variation of target lesions in treated patients with measurable disease and at least one radiological tumor assessment at all dose levels in Group A (paclitaxel plus lurbinectadin) (n = 49), and in Group B (paclitaxel plus lurbinectadin and BEV) (n = 9). BEV, bevacizumab; DL, dose level; EOC, epithelial ovarian cancer; MBC, metastatic breast cancer; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; PD, progressive disease; PR, partial response; RD, recommended dose; SCLC, small cell lung cancer; TN, triple negative.
Efficacy

Fifty-one patients in Group A and 10 patients in Group B were evaluable for efficacy. Four patients in Group A and 2 in Group B were not evaluable because no tumor evaluations were conducted after baseline imaging.

In Group A, 20 patients had confirmed responses, including one complete response (CR) (overall response rate [ORR] = 39%; 95% CI, 25.8–53.9%) and 11 patients had stable disease (SD) ≥ 3 months (clinical benefit rate [CBR] = 61%; 95% CI, 46.1–74.2%) at all dose levels, with objective tumor shrinkage in 35 (71%) of 49 evaluable patients (Fig. 1). The median progression-free survival (PFS) was 3.9 months (95% CI, 1.9–5.6 months) and the median DoR was 2.6 months (95% CI, 2.0–6.1 months). Thirteen confirmed responses (including one CR) and 6 SD ≥ 3 months occurred at the RD (ORR = 39%, 95% CI, 22.9–57.9%; CBR = 58%, 95% CI, 39.2–74.5%), with objective tumor shrinkage in 22 (69%) of 32 evaluable patients (Table 3 and Fig. 1). At the RD, the median PFS was 3.9 months (95% CI, 2.1–8.3 months) and the median DoR was 4.1 months (95% CI, 1.9–5.6 months) and the median DoR was 2.6 months (95% CI, 1.9–5.6 months) and the median DoR was 2.6 months (95% CI, 1.9–5.6 months) and the median DoR was 2.6 months (95% CI, 1.9–5.6 months). The highest ORRs were found in endometrial cancer (ORR = 36%, 95% CI, 29.0–96.3%; CBR = 86%; 95% CI, 42.1–99.6%).

Clinical benefit for > 12 months was observed in 5 patients: 4 in Group A (3 at the RD) and one in Group B. These patients had SCLC (n = 2), epithelial ovarian, endometrial cancer, and NSCLC (n = 1 each), had received 1–3 prior chemotherapy lines, and were given 18–35 cycles of study treatment each (all with PR as best response). Four of these patients showed no signs of disease progression prior to study termination.

Pharmacokinetics

All patients were sampled for PK analysis and were suitable for non-compartmental analysis (NCA). Parameters obtained for paclitaxel and lurbinectedin at each dose level are shown in Supplemental Information. Wide variability was observed in lurbinectedin and paclitaxel total clearance (CL). No dose linearity could be established for lurbinectedin maximum concentration (C_{max}) and area under the concentration–time curve (AUC). Potential drug-drug

Table 3 Antitumor activity according to RECIST in patients evaluable for efficacy at the recommended dose for phase II studies, with or without BEV

|                | Group A | Group B |
|----------------|---------|---------|
|                | (Paclitaxel 80 mg/m² / lurbinectedin 4.0 mg FD or 2.2 mg/m²) | (Paclitaxel 80 mg/m² / lurbinectedin 2.2 mg/m² / BEV 15 mg/kg) |
| n %            | n       %         |
| CR             | 1       3         | 1       10        |
| PR             | 12      36        | 4       40        |
| SD ≥ 3 mo      | 6       18        | 4       40        |
| SD < 3 mo      | 1       3         |                   |
| PD             | 12      36        |                   |
| Early PD       | 1       3         |                   |
| TF             | 1       10        |                   |
| ORR (%) (95% CI) | (22.9–57.9%) | (18.7–81.3%) |
| CBR (%) (95% CI) | 58%      | 90%            |
| Median DoR (months) (95% CI) | (2.1–8.3) | (1.4–n.r.) |

BEV bevacizumab, CBR clinical benefit rate, CI confidence interval, CR complete response, D Day, DL dose level, DoR duration of response, FD flat dose, MTD maximum tolerated dose, n.r. not reached, ORR overall response rate, PD progressive disease, PR partial response, q3wk every three weeks, RD recommended dose, RECIST Response Evaluation Criteria In Solid Tumors, SD stable disease, TF treatment failure
interactions (DDIs) between paclitaxel and lurbinectedin could not be fully ruled out, since a slight decrease in the CL of each drug was observed at the high AUC of the other drug. No statistically significant differences were observed in the PK parameters of paclitaxel and lurbinectedin in the presence or absence of BEV. Additional details are provided in Supplemental Information.

Discussion

This clinical trial defined the RD for phase II studies of paclitaxel plus lurbinectedin combination at paclitaxel 80 mg/m² on D1 and D8, and lurbinectedin 2.2 mg/m² on D1, q3wk.

The safety profile of the paclitaxel plus lurbinectedin combination was predictable. Myelotoxicity at the RD was common but reversible and manageable, and most non-hematological toxicities were mild/moderate. As expected, severe myelotoxicity and some non-hematological toxicities (vomiting, and especially neuropathy and alopecia) were slightly more frequent at this RD compared to the established dose for lurbinectedin monotherapy (3.2 mg/m² q3wk) [16, 17]. This may be attributed to the addition of paclitaxel, as these toxicities are commonly reported with single-agent paclitaxel [18–20]. No patients treated with the combination discontinued treatment due to toxicity, thereby further suggesting an acceptable safety profile.

As expected, the addition of BEV 15 mg/kg q3wk to this RD increased the incidence of some treatment-related toxicities.
Investigational New Drugs (2022) 40:1263–1273

m2 /week) and were associated with a lower incidence of effects on the PK profile of either lurbinectedin or paclitaxel. marginal, based on the slight changes in CL and the large vari-

dicty, which was manageable, the triple combination of pacli-
marginal toxicity, which was manageable, the triple combination of pacli-
taxel, lurbinectedin and BEV was generally well tolerated.

Encouraging antitumor activity was observed herein with the paclitaxel plus lurbinectedin combination in several indications. Recognizing the limitations of cross trial comparisons, the response rates at the RD without BEV were higher than those reported for lurbinectedin monotherapy in second-line treatment of patients with SCLC (80% vs. 35%) [16], BRCA-unselected breast cancer (50% vs. 9%) [23], and ovarian cancer (33% vs. 14–23%) [17, 24]. With the limitation of the small number of patients with each tumor type treated in this study, administration of paclitaxel plus lurbinectedin at the RD without BEV resulted in higher response rates in relapsed/refractory SCLC (80% vs. 20–27%) [25] and metastatic breast cancer (50% vs. 22–42%) [26, 27], and a similar response rate in relapsed ovarian cancer (33% vs. 21–60%) [20], compared with single-agent weekly paclitaxel at the dose commonly used in clinical practice (i.e., 80 mg/m²/week). These effects were achieved at a lower paclitaxel dose intensity (50.3 mg/m²/week vs. 72–78 mg/ m²/week) [20] and were associated with a lower incidence of peripheral neuropathy (all grades, 27% vs. 50–100%; grade 3/4, 0% vs. 3–21%) [25, 27–31]. Finally, in patients with endometrial cancer, the response rate of 27% achieved at the RD without BEV compares favorably with the modest response rates (≤15%) reported in trials evaluating second-line chemotherapies in this indication, with the highest ones being found with ifosfamide [32] and ixabepilone [33, 34].

The addition of BEV improved response rate to the combination at the RD in patients with epithelial ovarian cancer (from 33 to 75%) and NSCLC (from 25 to 33%). This is in line with the finding, in previous studies, of a 15–20% improvement in ORR with the addition of BEV to chemotherapy vs. chemotherapy alone in patients with recurrent ovarian cancer [12, 22, 35] and previously untreated NSCLC [9, 36, 37].

The PK parameters of paclitaxel and lurbinectedin in the present study were generally similar to those reported elsewhere [6, 38]. The absence of linearity found for lurbinectedin Cmax and AUC was probably due to the dose levels explored being very close. DDIs between paclitaxel and lurbinectedin could not be ruled out, although their clinical relevance would be marginal, based on the slight changes in CL and the large variability of PK parameters observed. BEV had no significantly effects on the PK profile of either lurbinectedin or paclitaxel.

In conclusion, weekly paclitaxel 80 mg/m² on D1 and D8 combined with lurbinectedin 2.2 mg/m² on D1 q3wk, with or without the addition of BEV 15 mg/kg on D1, showed a manageable overall safety profile and promising antitumor activity in patients with selected advanced solid tumors. These results support further development of this combination without BEV in the treatment of SCLC, breast, and endometrial cancer, and with added BEV in the treatment of epithelial ovarian cancer.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10637-022-01281-z.

Acknowledgements Authors thank all the motivated patients, the caregivers who enrolled on the trial, and all the clinical trial support staff in all the enrolling sites.

Author contributions E.C., C.S., G.H., M.d.M. and A.S. collected and interpreted data, critically reviewed the paper drafts and provided final approval of the paper to be published. A.D. helped conceive the design of the study, collected and interpreted data, critically reviewed the paper drafts and provided final approval of the paper to be published. C.K. helped conceive the design of the study, analyzed and interpreted data, critically reviewed the paper drafts and provided final approval of the paper to be published. X.E.-L.-E. analyzed and interpreted data, contributed to the initial writing of the paper, critically reviewed the paper drafts and provided final approval of the paper to be published. M.S. and C.F.-T. analyzed and interpreted data, critically reviewed the paper drafts and provided final approval of the paper to be published. M.C.-Y. analyzed and interpreted data, contributed to the initial writing of the paper, critically reviewed the paper drafts and provided final approval of the paper to be published.

Funding The study was funded by Pharma Mar S.A., including grants from the Centro para el Desarrollo Tecnológico Industrial (CDTI) during the conduct of the study. Dr. Drilon was supported in part by the National Cancer Institute of the National Institutes of Health P30 CA008748.

Data availability Individual participant data are not publicly available since this requirement was not anticipated in the study protocol considering that this trial started patient enrolment in 2013. Clinical trial summary results were placed at ClinicalTrials.gov (https://www.clinicaltrials.gov).

Declarations

Ethics approval The study was approved by the Research Ethics Committees of participating centers in the U.S., Spain and Switzerland.

The study was conducted in full accordance with the principles of the World Medical Association Declaration of Helsinki, the International Conference on Harmonisation, and all applicable local guidelines and regulations on good clinical practice.

Consent to participate Written informed consent was obtained from all individual patients included in this study.

Consent to publish All patients provided written informed consent about participation in this study and the use of collated data. No individual patient data are included in this article that could be used to identify any individual.

Competing interests M. de Miguel reports research funding from MSD, Basilea, Faron, Achilles, Pharmamar, Roche, Regeneron, Nektar, Loxo, Gennmab, Cytomex, Bayer, AstraZeneca, Novartis, Abbvie, Array, Eisai, and Sanofi; and Speaker’s Bureau membership for MSD, Janssen, and Roche; all outside the submitted work. C. Kahatt reports personal fees for salary as full time employee and stock ownership from Pharma Mar, outside the submitted work. X.E. Luepke-Estefan, M. Siguero and M. Culler-Yong report personal fees for salary as full time employee from
Pharma Mar, outside the submitted work. C. Fernandez-Teruel was an employee of Pharma Mar at the time the study was carried out. A. Stathis reports institutional grants for clinical trials from Merck, Bayer, Roche, Novartis, Pfizer, ADC Therapeutics, MEI Pharma, Eli Lilly, and Pharma Mar; a consultant position with Bayer, Eli Lilly, Roche, and Novartis; and travel grants from Abbvie and Pharma Mar; all outside the submitted work. A. Drilon reports research grants from Foundation Medicine; associated research grants (paid to institution) from Pfizer, Exelixis, GlaxoSmithKline, Teva, Taiho, and Pharma Mar; an advisory board position with Ignitya/Genentech/Roche, Loox/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14er/Elevation Oncology, ArcherDX, Merogenos, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedia Ltd., mBrace, AXIS, EPG Health, Harborside Nexus, Libervum, RV More, Olgem, Aymgen, TouchME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science Inc, I3 Health, AiCMEx, and Monte Rosa; CME honoraria from Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, EPG Health, JNCC/Harborside, Libervum, and Remedia Ltd.; royalties from Wolters Kluwert; equity from Treeline Bio; copyright from Selpercatinib-Osimertinib (filed/pending); and other support from Merck, Puma, Merus, and Boehringer Ingelheim; all outside the submitted work. No potential conflicts of interest were disclosed by the other authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Cuevas C, Perez M, Martin MJ, Chicharro JL, Fernandez-Rivas C, Flores M, Francesch A, Gallego P, Zarzuillo M, De La Calle F, Garcia J, Polanco C, Rodriguez I, Manzanares I (2000) Synthesis of eteicinascidin ET-743 and phthalascidin Pt-650 from cyanosarcin B. Org Lett 2(16):2545–2548
2. Buen-Calabuig JA, Giraudon C, Galmarini CM, Egly JM, Gago F (2011) Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations. Nucleic Acids Res 39(18):8248–8257
3. Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D’incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM and Grohar PJ (2016) Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus. Cancer Res 76(22):6657–6668
4. Santamaría Nunez G, Robles CM, Giraudon C, Martinez-Leal JF, Compe E, Coint F, Aviles P, Galmarini CM, Egly JM (2016) Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol Cancer Ther 15(10):1–14
5. Leal JF, Martinez-Diez M, Garcia-Hernandez V, Moneo V, Domingo A, Buen-Calabuig JA, Negri A, Gago F, Guillen-Navarro MJ, Aviles P, Cuevas C, Garcia-Fernandez LF, Galmarini CM (2010) PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol 161(5):1099–1110
6. Elez ME, Tabernero J, Gearly D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Sigüero M, Cullell-Young M, Zyldierge-maj S, Ratain MJ (2014) First-in-human phase I study of Lurbi-nectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res 20(8):2205–2214
7. Guillen MJ, Cataluña O, Palomares M, Lopez R, Nuñez P, Cuevas C and Aviles P (2013) Lurbinectedin (PM01183) in vivo synergizes the antitumor activity of taxanes. Cancer Res 73(8 Suppl):Abstract 5495
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Grifﬁng S, Holmgren E, Ferrara N, Fyle G, Rogers B, Ross R, Kabbabifar V (2004) Bevacizumab plus irinotecan, ﬂuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342
9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilienbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 354(24):2524–2530
10. Giantonio BJ, Catalano PJ, Meropol NJ, O’dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB, 3rd and Eastern Coopera-tive Oncology Group Study E (2007) Bevacizumab in combina-tion with oxaliplatin, ﬂuorouracil, and leucovorin (FOLF/X4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539–1544
11. Tewari KS, Sill MW, Long HJ, 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370(8):734–743
12. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Soro R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELLA open-label randomized phase III trial. J Clin Oncol 32(13):1302–1308
13. Lima AB, Macedo LT, Sasse AD (2011) Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a system-atic review and meta-analysis. PLoS ONE 6(8):e22681
14. National Cancer Institute (2009) Common Terminology Criteria for Adverse Events v.4.0 (CTCAE).
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):2243–2247
16. Trigo J, Subbiah V, Besse B, Moreno V, Lopez R, Sala MA, Peters S, Ponce S, Fernandez C, Alfaro V, Gomez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martinez M, Delord JP, Awada A, Kruseitel R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D’arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L (2020) Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 21(5):645–654
17. Gaillard S, Oaknin A, Ray-Coquard I, Vergote I, Scambia G, Calombo N, Fernandez C, Alfaro V, Kahatt C, Nieto A, Zeaiter A, Aracil M, Vidal L, Pardo-Burdalo B, Papai Z, Kruestele IT, O’malley DM, Benjamin I, Pautier P and Lorusso D (2021) Lurbi-nectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter,
randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol 163(2):237–245
18. Eisenhauer EA, Ten Boekel Huink WW, Swenerton KD, Gianni L, Myles J, Van Der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N et al (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12(12):2654–2666
19. Spencer CM and Faulds D (1994) Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48(5):794–847
20. Baird RD, Tan DS, Kaye SB (2010) Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol 7(10):575–582
21. Perren TJ, Swart AM, Pfiisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, Du Bois A, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Lemenin A, Plante M, Stark D, Qian W, Parmar MK, Oza AM, Investigators I (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484–2496
22. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30(17):2039–2045
23. Cruz C, Llop-Guevara A, Garber JE, Arun BK, Perez Fidalgo JA, Lluch A, Telli ML, Fernandez C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Perez De La Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra B, Balmana J, Isakoff SJ (2018) Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. J Clin Oncol 36(31):3134–3143
24. Poveda A, Del Campo JM, Ray-Coquard I, Alexandre J, Provansal M, Guerra Alia EM, Casado A, Gonzalez-Martín A, Fernández C, Rodriguez I, Soto A, Kahatt C, Fernandez Teruel C, Galmarini CM, Perez De La Haza A, Bohan P, Berton-Rigaud D (2017) Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. Ann Oncol 28(6):1280–1287
25. Yamamoto N, Tsurtani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, Kudoh S, Takada M, Minato Y, Fukuoka M (2006) Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res 26(1B):771–781
26. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19(22):4216–4223
27. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Umberto P, Unger P, North L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26(10):1642–1649
28. Ota S, Sugiyama T, Komai K, Hirai N, Kumagai S, Ushijima K, Nishida T, Kamura T (2001) Weekly 1 hour paclitaxel infusion in patients with recurrent gynecological tumors: a pilot study. Jpn J Clin Oncol 31(8):395–398
29. Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, Baker M (2002) Phase II trial of single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20(9):2365–2369
30. Ghamande S, Lele S, Marchetti D, Baker T, Onduski K (2003) Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer 13(2):142–147
31. Kita T, Kikuchi Y, Takano M, Suzuki M, Oosawa M, Konno R, Yamamoto K, Inoue H, Seto H, Yamamoto T, Shimizu K (2004) The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol 92(3):813–818
32. Sutton GP, Blessing JA, Homesley HD, Mcguire WP, Adcock L (1994) Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study Cancer 73(5):1453–1455
33. Dizon DS, Blessing JA, Mcmeekin DS, Sharma SK, Disilvestro P, Alvarez RD (2009) Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol 27(19):3104–3108
34. Mcllreath LE, Baird RD, Barter J, Scambia G, Manzyuk L, Llop-Guevara A, O’Brian A, Ringueutt S, Mkhshaphalay P, Rosenberg J, Vergote I (2015) Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol 138(1):18–23
35. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DG, Walker JL, Kim BG, Fujiwara K, Tewari K, O’mailley DM, Davidson SA, Rubin SC, Disilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R and Mannel RS, (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18(6):779–791
36. Reck M, Von Pawel J, Zatloukal P, Ramla R, Gorbounova V, Hirsh V, Leigl N, Mezger J, Archer V, Moore N, Manegold C and Group BOS (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAil). Ann Oncol 21(9):1804–1809
37. Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY (2015) BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 33(19):2197–2204
38. Chu Q, Mita A, Forouzesh B, Tolcher AW, Schwartz G, Nieto A, Soto-Matos A, Alfaro V, Lebedinsky C, Rowinsky EK (2010) Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clin Cancer Res 16(9):2656–2665

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.